South Korea Leiomyosarcoma Treatment Market Size & Outlook, 2025-2033

South Korea Leiomyosarcoma Treatment Market Insights

Based on Reed Intelligence findings, the South Korea Leiomyosarcoma Treatment Market reached USD 9.24 Million in 2024 and is estimated to attain USD 14.12 Million by 2033.
From 2026 to 2033, the South Korea market is expected to grow at a steady CAGR of 4.85%.
Within the Treatment Type category, Surgery dominated in 2024 in terms of market size contribution.
Over the forecast period, Targeted Therapy is forecasted to deliver the fastest growth, positioning it as the most lucrative Treatment Type segment.

Other Key Findings

In 2024, South Korea accounted for 0.86% of the global Leiomyosarcoma Treatment Market size.
By 2033, United States is expected to lead the global Leiomyosarcoma Treatment Market in terms of market size.
Within Asia Pacific, China is projected to dominate the regional Leiomyosarcoma Treatment Market size by 2033.
Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 18.99 Million by 2033.

Report Summary

Report Scope	Details
Base Year for Study	2024
Study Period	2021-2033
Historical Period	2021-2023
Forecast Period	2025-2033
Market Size In 2024	USD 9.24 Million
Market Size In 2033	USD 14.12 Million
Largest segment	Surgery
Units	Revenue in USD Million
CAGR	4.85% (2025-2033)
Segmnetation Covered
Treatment Type	Surgery Radiotherapy Chemotherapy Targeted Therapy
Disease Stage	Localized Locally Advanced Metastatic
End User	Hospitals Specialty Clinics Ambulatory Surgical Centers
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

South Korea Leiomyosarcoma Treatment Market Treatment Type 2025-2033 (USD Million)

Treatment Type	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Surgery	XX.x	XX.x	XX.x	3.81	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Radiotherapy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Chemotherapy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Targeted Therapy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

South Korea Leiomyosarcoma Treatment Market Disease Stage 2025-2033 (USD Million)

Disease Stage	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Localized	XX.x	XX.x	XX.x	4.17	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Locally Advanced	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Metastatic	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

South Korea Leiomyosarcoma Treatment Market End User 2025-2033 (USD Million)

End User	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Hospitals	XX.x	XX.x	XX.x	4.29	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ambulatory Surgical Centers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.